{"id":71092,"date":"2023-03-27T20:05:41","date_gmt":"2023-03-27T18:05:41","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=71092"},"modified":"2023-03-28T11:14:38","modified_gmt":"2023-03-28T09:14:38","slug":"nicola-magrini-nuovo-direttore-dellunita-di-qualita-e-governo-clinico-dellausl-romagna","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/nicola-magrini-nuovo-direttore-dellunita-di-qualita-e-governo-clinico-dellausl-romagna\/","title":{"rendered":"Nicola Magrini new Director of the Quality and Clinical Governance unit of the Romagna Ausl"},"content":{"rendered":"<h2 class=\"entry-title\">Nicola Magrini introduces himself, the new Director of the Quality and Clinical Governance unit of the Romagna Ausl<\/h2>\n<p><a href=\"https:\/\/www.ravennawebtv.it\/si-presenta-nicola-magrini-nuovo-direttore-dellunita-di-qualita-e-governo-clinico-dellausl-romagna\/\" target=\"_blank\" rel=\"noopener\">ravennawebtv \u2013 March 27, 2023<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-71096 alignright\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/03\/magrini-primari-ausl-romagna-238716.660x368.jpeg\" alt=\"\" width=\"404\" height=\"225\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/03\/magrini-primari-ausl-romagna-238716.660x368.jpeg 660w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2023\/03\/magrini-primari-ausl-romagna-238716.660x368-300x167.jpeg 300w\" sizes=\"auto, (max-width: 404px) 100vw, 404px\" \/>Officially presented to the press Nicola Magrini, new director of the Quality and Clinical Governance Unit of the Romagna Ausl, whose appointment in recent weeks had been at the center of controversy, especially from the center-right and the Brothers of Italy.<\/p>\n<p>Former director of the Italian Medicines Agency, founding member of the Italian Cochrane Center, a network that studies the effects of health interventions, former director of the WHO Collaborative Center, Magrini&#039;s first objective will be to reduce health care costs in Romagna.<\/p>\n<p>The first interventions will almost certainly be dedicated to reducing the cost of pharmaceutical expenditure. As for the controversies, it was the director of the health company Tiziano Carradori himself who extinguished them in the press conference: Magrini&#039;s curriculum cannot be criticized and the salaries of managers are regulated by national regulations.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Note:<em> Magrini&#039;s appointment will have a five-year term. An assignment worth 146,031.67 euros a year - for a total figure of more than 730,000 euros - which had already triggered criticism at the end of January, with controversies mainly coming from the League.\u00a0<\/em><em>Luca Bartolini, Forl\u00ec coordinator of Fratelli d&#039;Italia:\u00a0<\/em><em>\u201cAnd then they say there are no resources.\u201d<\/em><\/p>\n<p>Related news: <a href=\"https:\/\/www.ilgiunco.net\/2023\/03\/27\/governo-della-spesa-farmaceutica-accordo-tra-due-asl-nasce-la-task-force-interaziendale\/\" target=\"_blank\" rel=\"noopener\">South East Tuscany. Government of pharmaceutical expenditure, agreement between two Local Health Authorities: the inter-company task force is born<\/a><\/p>\n<p><a href=\"https:\/\/www.fimmg.org\/index.php?action=pages&amp;m=view&amp;p=18&amp;art=5317\" target=\"_blank\" rel=\"noopener\">Liguria family doctors to councilor Gratarola: \u201cInappropriate prescriptions? A category is offended\u201d<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Si presenta Nicola Magrini, nuovo Direttore dell\u2019unit\u00e0 di Qualit\u00e0 e Governo Clinico dell\u2019Ausl Romagna ravennawebtv &#8211; 27 marzo 2023 Presentato ufficialmente alla stampa Nicola Magrini, nuovo direttore dell\u2019Unit\u00e0 Operativa di Qualit\u00e0 e Governo Clinico dell\u2019Ausl Romagna, la cui nomina nelle scorse settimane era stata al centro di polemiche, provenienti in particolare dal centrodestra e da &hellip;<\/p>","protected":false},"author":4,"featured_media":71098,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[49,26,79],"class_list":["post-71092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-aifa","tag-spesa-farmaceutica","tag-ssn"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/71092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=71092"}],"version-history":[{"count":7,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/71092\/revisions"}],"predecessor-version":[{"id":71108,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/71092\/revisions\/71108"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/71098"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=71092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=71092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=71092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}